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Abstract
Background: Sensorineural hearing loss (SNHL) is one of the major long term side effects from radiation therapy
(RT) in nasopharyngeal cancer (NPC) patients. This study aims to review the incidences of SNHL when treating with
different radiation techniques. The additional objective is to determine the relationship of the SNHL with the
radiation doses delivered to the inner ear.
Methods: A retrospective cohort study of 134 individual ears from 68 NPC patients, treated with conventional RT
and IMRT in combination with chemotherapy from 2004-2008 was performed. Dosimetric data of the cochlea were
analyzed. Significant SNHL was defined as > 15 dB increase in bone conduction threshold at 4 kHz and PTA (pure
tone average of 0.5, 1, 2 kHz). Relative risk (RR) was used to determine the associated factors with the hearing
threshold changes at 4 kHz and PTA.
Results: Median audiological follow up time was 14 months. The incidence of high frequency (4 kHz) SNHL was
44% for the whole group (48.75% in the conventional RT, 37% with IMRT). Internal auditory canal mean dose of >
50 Gy had shown a trend to increase the risk of high frequency SNHL (RR 2.02 with 95% CI 1.01-4.03, p = 0.047).
Conclusion: IMRT and radiation dose limitation to the inner ear appeared to decrease SNHL.
Background
Radiation therapy (RT) is the standard treatment for
nasopharyngeal cancer (NPC) patients as a result of the
relative radiosensitivity, deep location and the close
proximity to the normal critical structures. High dose
RT of ≥ 66 Gy in combination with chemotherapy has
yielded a 5-year locoregional control for more than 80%
of the patients with locally advanced disease [1-3]. Con-
sequently, RT produces undesirable side effects on the
adjacent organs. In addition to xerostomia, sensorineural
hearing loss (SNHL), resulting from the cochlea damage,
is one of the major long term side effects which impacts
the patients’ quality of life. With modern conformal
radiation techniques, the incidence of radiation induced
SNHL is expected to decline, due to a better
visualization of the organs on the planning CT images
and a better capability to spare the cochlea with a mean
dose < 40-50 Gy [4-7].
This retrospective analytic study aims to report the
incidences of SNHL of NPC patients receiving chemora-
diotherapy with conventional RT comparing with inten-
sity modulated radiation therapy (IMRT). To our
knowledge, this study is the first one to compare hear-
ing status between conventional RT and IMRT for NPC
patients. As most earlier studies had some disagreement
about the cochlea contouring for dose volume analysis,
the further aim of this study is to evaluate radiation
doses in each specific part of the inner ear [cochlea,
inner ear (cochlea and vestibule) and internal auditory
canal (IAC)] in correlation with the incidences of SNHL.
Methods
The medical records, including radiation dosimetric data
and audiological assessment of the 507 NPC patients
* Correspondence: sijps@mahidol.ac.th
1Division of Radiation Oncology, Faculty of Medicine Siriraj Hospital,
2 Prannok Rd, Bangkoknoi, Bangkok, Thailand
Full list of author information is available at the end of the article
Petsuksiri et al. Radiation Oncology 2011, 6:19
http://www.ro-journal.com/content/6/1/19
© 2011 Petsuksiri et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.receiving definitive RT at the division of Radia-
tion Oncology, Siriraj Hospital from January 2004 to
December 2008 were retrospectively reviewed under the
approval of the Siriraj institutional review board.
Two hundred and four NPC patients with T1-T4,
N0-N3, M0 diseases (according to AJCC 1997 staging
system) who completed RT courses with either conven-
tional RT or IMRT with baseline pre RT audiograms
were included. Patients were excluded from the study
when they had no medical records, no post RT audio-
grams, or not completed RT. Patients who had tumor
invasion into the inner ear or had a recurrent disease
were also excluded. No patients were excluded because
of a hearing impairment during RT. Patients who had
severe hearing impairment (pure tone average: PTA, at
0.5, 1, 2 kHz > 50 dB in both ears) on pre RT audio-
grams were excluded. Each individual ear was evaluated
independently for radiation doses and hearing status.
Ultimately, 134 individual ears with intact hearing status
were included for data analysis (Figure 1).
Radiation therapy
The radiation technique has changed from conventional
RT (before 2007) to IMRT (since 2007) due to machine
evolution at our institute. After the start of the IMRT
era, all patients with a curative aim were treated with
IMRT. Therefore, 41 patients were treated with conven-
tional RT and 27 patients were treated with IMRT. For
the conventional RT, radiation was prescribed to a total
dose of 66-70 Gy at 2 Gy per fraction, 5 fractions per
week. All patients were treated with a Cobalt 60 tele-
therapy unit. Parallel opposed portals were used for the
primary tumor site and the upper neck. Spinal cord and
brainstem were mostly shielded at the dose of 46 Gy.
This conventional field generally included the base of
the skull, for which the inner ear was not intentionally
protected by the posterior fossa block. The lower neck
was routinely treated with the anterior split field.
For IMRT, the target volumes and normal tissue
structures were defined by using CT images. The gross
target volume (GTV) consisted of the gross primary
tumor and involved lymph nodes as defined by contrast
enhancement CT. Generally, clinical target volume
(CTV) high risk was defined by adding a 5-mm margin
to GTV. A smaller margin (3 mm) was accepted for the
margin that was in close proximity to the critical struc-
tures, such as brainstem, optic nerves and optic chiasm.
CTV intermediate and low risk regions were contoured
according to the RTOG recommendation [8]. Planning
target volume (PTV) was defined by adding a 5-mm
margin to the CTVs in all dimensions to include setup
uncertainties. Radiation doses were prescribed simulta-
neously to total doses of 66-70 Gy to the high risk
region, 59.4-63 Gy to the intermediate-risk region, and
50.4-57 Gy to the low-risk region, in 33-35 fractions.
The primary tumor and the upper neck were treated
with IMRT. For the lower neck region, either continuing
IMRT with the upper neck part or with the anterior
spilt field was allowed.
Dose Calculation of the Inner Ear
Dose calculation of the inner ear was not accessible for
patients who received conventional RT. For the patients
who were treated with IMRT, dose calculations to the
inner ear were evaluated. Initially, the inner ears
(cochlea and vestibule) were contoured and constrained
(mean doses constraint of 35 Gy with doses accepted at
50 Gy) at the time of radiation treatment planning. Each
of the inner ear structures was re-contoured (using
bone window; window width = 2000 HU, window level
= 400 HU) and reviewed by the authors (JP and AS) as
in Figure 2. We defined the inner ear as a combination
of the cochlea and vestibule. The purpose of the inner
ear delineation was to compare its’ dose with the prior
studies that defined the inner ear as a cochlea for SNHL
evaluation [6,7]. The IAC was contoured to evaluate the
radiation doses to the cochlea nerve, which can be
affected by radiation. The minimum dose, maximum
dose and mean dose were recalculated for each part of
the auditory pathway.
Chemotherapy
Patients with locally advanced disease received concur-
rent intravenous platinum-based chemotherapy (Cispla-
tin or Carboplatin). Cisplatin was given with 100 mg/m
2
every 3 weeks during the radiation course, followed by
Figure 1 Patients flow diagram.
Petsuksiri et al. Radiation Oncology 2011, 6:19
http://www.ro-journal.com/content/6/1/19
Page 2 of 8Cisplatin 80 mg/m
2 at day 1 and 5-FU 1000 mg/m
2 at
day 1-4 every 3 weeks. Carboplatin was allowed in
patients with poor renal function or were intolerant to
C i s p l a t i n .C a r b o p l a t i nw a sg i v e ni naw e e k l yf a s h i o n
(AUC 2) during the radiation course, followed by adju-
vant Carboplatin (AUC 5 at day 1) in combination with
5-FU (1000 mg/m
2 at day 1-4) every 3 weeks. Type (Cis-
platin or Carboplatin), doses, and cycles of chemother-
apy were recorded.
Audiological assessment
Pre and post RT audiological data were reviewed. The
audiograms were ordered routinely for all patients at
pre RT and post RT periods by ENT physicians per our
hospital’s policy. The bone conduction (BC) threshold
was measured at 0.5-4 kHz to detect the early SNHL
from the cochlea and/or IAC damages. BC threshold at
4 kHz was selected to represent the high frequency loss.
The pure tone average (PTA), an average of threshold
levels at 0.5 kHz, 1 kHz and 2 kHz, was chosen to
reflect the threshold in the low frequency speech range
[9,10]. Post RT audiograms (at least 6 months after
completion of RT) were obtained at various intervals.
The most recently performed audiograms were used for
the analysis. Hearing threshold changes were determined
by comparing with their pre RT baselines. As per the
American Speech and Hearing Association guidelines,
significant SNHL was defined as a ≥ 10 dB increase at
two consecutive frequencies or ≥ 15 dB at one fre-
quency. Hence, the cut-off point of ≥ 15 dB increase
from baseline in BC threshold at 4 kHz was used as a
criterion for SNHL in this study.
The incidences of otitis media effusion (OME) and
tympanic membrane perforation were documented at
baseline and follow up. Influences from age, chemother-
apy, OME, co-morbidities (DM and hypertension),
radiation techniques and the radiation doses on the
change of BC thresholds were assessed.
Statistical methods
The statistics program STATA, version 8 was employed
for data analysis. Relative risk (RR) with 95% confiden-
tial interval (CI) was used to determine the relationship
between the possible associated factors and the thresh-
old changes at 4 kHz and PTA. We tested the null
hypothesis as to whether the relative risk was equal to 1
by calculating the chi-square test statistics.
Results
From January 2004 to December 2008, 68 patients (41
patients with conventional RT, 27 patients with IMRT)
were enrolled for the hearing analysis. The patients’
characteristics were shown in Table 1. Sixty six patients
(97.1%) received concurrent chemoradiotherapy and
only 2 patients (2.9%) received RT alone.
Radiation doses to the inner ear
For 41 patients who received conventional RT, dosi-
metric data were not available. For 27 patients who
received IMRT, 54 ears were re-analyzed. Mean doses to
the cochlea, inner ear and IAC were 51.02 Gy (range
25.09 - 75.54), 45.32 Gy (range 19.86-75.55) and 50.51
Gy (range 27.75-73.29), respectively.
Figure 2 Inner ear contouring.C :C o c h l e a ,V :V e s t i b u l e ,I A C :
internal auditory canal Inner ear = cochlea(C) + vestibule (V).
Table 1 Patient characteristics (Total 134 individual ears,
68 patients)
Characteristics Value (68 patients)
Age (18-70 years old) Median 47.5 years old
≤ 50 44 (65%)
> 50 24 (35%)
Co-morbidities (patients)
DM and/or Hypertension 14 (20.6%)
No co-morbidities 54 (79.4%)
Pre RT otitis media (ears)
Yes 34 (25.4%)
No 71 (53%)
No data 29 (21.6%)
Post RT otitis media (ears)
Yes 31 (23.1%)
No 93 (69.4%)
No data 10 (7.5%)
Tumor stage
I/II 15 (22.1%)
III/IV 53 (77.9%)
Pathology (WHO 2005)
WHO type 1 (SCC, keratinized) 24 (35.2%)
WHO type 2 (SCC, non-keratinized) 4 (5.9%)
WHO type 2.2 (Undifferentiated) 38 (55.9%)
Others 2 (3%)
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Chemotherapy was given to 97% of the patients (66/68
patients). Most of the patients received concurrent che-
moradiotherapy followed by adjuvant chemotherapy.
Sixty two patients received Cisplatin, while 4 patients
received Carboplatin. The total accumulative doses of
Cisplatin ranged from 120 mg to 980 mg (median dose
689 mg, mean dose 639 ± 233 mg). Carboplatin accu-
mulative doses ranged from 200 mg to 2100 mg (med-
ian dose 980 mg, mean 988 ± 670 mg).
Treatment outcomes
Median follow up time for all patients was 27.5 months
(range 8-65 months). At the end of the study, 13 out of
68 patients were lost to follow up. The 2 year-progres-
sion free survival of this study group was 76.4% with a
2 year locoregional control of 88.5%.
Audiological assessment and the incidences of post
radiation SNHL
Pre RT audiograms demonstrated that 65.5% of the ears
(88/134 ears) were normal or had mild BC hearing
losses (16-25 dB) at 4 kHz. At PTA, 91% of the ears
(122/134 ears) were normal or had mild hearing losses.
Post RT audiograms were performed at different fol-
low up intervals. The median follow up time of audiolo-
gical assessment for all 68 patients was 14 months
(range 6-43 months). Median audiological follow up
times for conventional RT and IMRT groups were 15
months (range 6-43 months) and 13 months (range 6-
29 months), respectively. For total of 68 patients (134
ears), the incidence of SNHL at high frequency (4 kHz)
was 52.9% (unilateral loss 13/68 patients, bilateral loss
23/68 patients). At PTA, the incidence of SNHL was
10.3% (unilateral loss 6/68 patients, bilateral loss 1/68
patients). For individual ear evaluation, the incidences of
SNHL were 44% (59/134 ears) and 6% (8/134 ears) at 4
kHz and PTA, respectively.
Factors associated with the incidences of SNHL
Radiation techniques
With conventional RT, the incidences of SNHL were
48.75% (39/80 ears) at 4 kHz and 5% (4/80 ears) at
PTA, respectively. With IMRT, the incidences of SNHL
were 37% (20/54 ears) at 4 kHz and 7.4% (4/54 ears) at
PTA, respectively.
Radiation doses to the cochlea, inner ear, and IAC
Mean radiation doses to the cochlea, inner ear and IAC
in this study were about 50 Gy, 45 Gy and 50 Gy,
respectively. The authors then evaluated the incidences
of SNHL based upon the mean radiation doses to each
inner ear structure as shown in Table 2.
On univariate analysis; IMRT, cochlea mean dose ≤ 50
Gy, inner ear mean doses ≤ 45 Gy and IAC mean dose
≤ 50 Gy appeared to have lower incidences of SNHL at
high frequency (4 kHz). The other associated factors,
including Cisplatin doses, OME, age and co-morbidities
of the patients were not demonstrated to affect the inci-
dence of SNHL (Figure 3). At PTA, there was no signifi-
cant factor affecting the incidence of SNHL (Figure 4).
Based on the literatures reviewed, most studies
reported that the incidences of SNHL were impacted by
mean cochlea doses in the range of 45-50 Gy [4,5,7,11].
We therefore did not re-explore the data as quantitative
continuous variables. Instead, we re-validated the known
cut-off point starting at 50 Gy, which was actually the
mean cochlea dose in our study. The lowermost cut-off
level at 45 Gy was chosen for analysis [7]. The data
showed that the RR for mean dose of > 45 Gy was 1.77
(95% CI 0.82-4.24) at 4 kHz, compared to dose ≤ 45 Gy.
This analysis showed that the incidence of SNHL was
not significantly changed when mean cut-off doses to
the cochlea decreased from 50 to 45 Gy.
Based on the cochlea nerve tolerance of 54 Gy, we
then explored the optimal radiation threshold to the
IAC by creating a hypothesis with a cut-off point of
Table 2 The incidences of SNHL and the inner ear mean
radiation dose (IMRT)
Mean radiation doses Total
54 ears
SNHL at 4 Hz
(ears)
SNHL at PTA
(ears)
Cochlea mean dose
≤ 50 Gy 24 6/24 (25%) 0/24 (0%)
> 50 Gy 30 14/30 (46.67%) 4/30 (13.3%)
Inner ear mean dose
≤ 45 Gy 29 8/29 (27.59%) 0/29 (0%)
> 45 Gy 25 12/25 (48%) 4/25 (16%)
IAC mean dose
≤ 50 Gy 31 8/31 (25.81%) 0/31 (0%)
> 50 Gy 23 12/23 (52.17%) 4/23 (17.4%)
Figure 3 Forest plot for relative risk of SNHL at 4 kHz.
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> 54 Gy was 2.25 (95% CI 1.14-4.17) compared to a
mean dose ≤ 54 Gy at 4 Hz.
As radiation techniques had a potential effect on
SNHL, we had analyzed the effect of IMRT on different
variables with bivariate analysis. The bivariate analysis
demonstrated that IMRT tended to decrease SNHL in
younger patients (≤ 50 years old) or healthy patients
without medical co-morbidities (DM and/or hyperten-
sion) (Table 3).
As NPC patients required Cisplatin chemotherapy to
ensure the local and distant control, SNHL was poten-
tially worse when combined with high radiation doses to
the hearing structures. The authors then performed a
bivariate analysis to evaluate the effects of Cisplatin on
radiation dose levels for each inner ear structure. An
accumulative Cisplatin dose of > 600 mg was used in
this analysis since the mean Cisplatin dose delivered was
about 600 mg in our study. The data demonstrated that
in patients who received higher dose of Cisplatin (> 600
mg), the incidences of SNHL tended to be higher if they
received mean radiation dose of > 50 Gy to the cochlea
and > 45 Gy to the inner ear (Table 4).
Discussion
Radiation induced SNHL has been recognized as an
important adverse effect which generally develops 6 to
24 months after radiation treatment and may progress
to complete deafness [10,12]. The inner ear is the most
susceptible organ for a durable long term SNHL. The
etiologies of RT induced SNHL are vascular insuffi-
ciency, reduced number of capillaries, degeneration of
endotheliocytes in vessels, loss of cells in the organ of
Corti, atrophy and degeneration of the stria vascularis,
and atrophy of the spiral ganglion cells and the cochlea
n e r v e[ 1 3 , 1 4 ] .T h i sd a m a g ei sm o r ep r o m i n e n tt ot h e
outer hair cells in the basal turn of the cochlea, which is
responsible for transduction of higher frequency sound
and a clinically significant SNHL at a higher frequency
(>2 Hz) might occur.
The incidences of radiation induced SNHL were
reported in the range of 0-65% with various radiation
techniques (Table 5). Our study demonstrated that the
incidences of SNHL were 44% (59/134 ears) at high fre-
quency (4 kHz) and 6% (8/134 ears) at PTA for the
whole population. Each study, however, was performed
and evaluated with different criteria and follow up times.
The median follow up time (14 months) for audiologi-
cal assessment in this study was rather shorter than the
other studies. Nonetheless, radiation induced ototoxicity
is typically evident at 6-12 months after completion of
radiation therapy [4]. Transient SNHL might occur up
to 41% of the patients as reported by Ho et al [12]. This
study was not able to evaluate the transient hearing loss
because of its retrospective design which was based
upon different follow up times.
The hospital’s policy is to routinely perform the audio-
logical assessment for all NPC patients. However, a
number of patients in our study did not complete the
audiological tests. We recognized that the completeness
of audiometric evaluation for every patient would be
challenging in the absence of a prospective clinical trial.
In this study, we compared the differences of pre and
Figure 4 Forest plot for relative risk of SNHL at PTA.
Table 3 Bivariate analysis (Effect of IMRT on different
variables)
Factors Relative risk Test for
homogeneity
Age (years old) p = 0.40
> 50 1.00 (95% CI 0.49-2.10)
≤ 50 0.68 (95% CI 0.39-1.18)
Cisplatin (total dose, mg) p = 0.57
> 600 mg 0.94 (95% CI 0.59-1.49)
≤ 600 mg 0.70 (95% CI 0.28-1.73)
Co-morbidities p = 0.36
Yes 1.11 (95% CI 0.45-2.78)
No 0.69 (95%CI 0.43-1.12)
Table 4 Bivariate analysis of Cisplatin effect on radiation
dose levels
Factors Relative risk Test for
homogeneity
Cochlea mean dose (Gy) p = 0.21
> 50 2.1 (95% CI 0.62-7.15)
≤ 50 0.63 (95% CI 0.15-2.67)
Inner ear mean dose (Gy) p = 0.14
> 45 3.06 (95% CI 0.51-18.33)
≤ 45 0.67 (95%CI 0.2-2.19)
IAC mean dose (Gy) p = 0.89
> 50 1.33 (95% CI 0.47-3.78)
≤ 50 1.18 (95% CI 0.29-4.81)
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hearing threshold to justify the SNHL. We also
excluded the patients who had only post RT audio-
grams. This should diminish the bias from patients
who performed audiological exams because of having
hearing impairment post RT.
The prior studies included only patients who com-
pleted the audiological assessment. This would poten-
tially alter the incidence of SNHL in a certain number
of patients who never performed the audiological exams.
Also, the usage of contralateral ear as a baseline could
create some inconsistency of the results [4,15,16]. Thus,
we assumed that the results of our study would be ade-
quate to report the incidence of SNHL although we
understood the weakness of retrospective data.
With different radiation techniques, IMRT was found
to have fewer incidence of SNHL when compared to the
conventional RT (37% vs 48.75%). There was a trend to
decrease the incidences of SNHL with IMRT in our
study (RR of 0.76 with 95% CI 0.5-1.15, favouring
IMRT). The former studies for NPC treatment had not
directly compared the incidences of SNHL between con-
ventional technique and conformal techniques. By indir-
ect comparison among studies, the incidences of SNHL
with the conformal techniques were not consistently
lower than the conventional technique as shown in
Table 5. The delineation of the normal structures and
radiation dose constraint are very important in IMRT
planning. IMRT potentially provides higher radiation
doses to the cochlea than three dimensional conformal
radiation technique, or even more than conventional
RT, if the cochlea is not intentionally avoided [17].
In this study, we had delineated the inner ear into
the cochlea and inner ear as there was some disagree-
ment of cochlea delineation among the earlier studies
[5,7]. Because of the tiny volume of the cochlea, target
delineation is essential for dose volume analysis. Espe-
cially, its location is in the high dose gradient of the
IMRT.
The results from our study demonstrated that the
incidence of high frequency SNHL tended to be
increased when mean dose delivered to the cochlea
was > 50 Gy. Earlier studies suggested that the inci-
dences of SNHL were increased with mean cochlea
doses > 45-50 Gy [4,5,7,11]. However, our exploratory
analysis showed that the incidence of SNHL was not
significantly changed when mean cut-off doses to the
cochlea decreased from 50 to 45 Gy. Therefore, our
study suggested that the mean cochlea dose of 50 Gy
should be reasonable since the excessive dose con-
straint to the cochlea would potentially compromise
the nearby targets coverage.
Apart from the cochlea, the IAC should be concerned
as the cochlea nerve traverses through the canal enter-
ing into the brainstem. The SNHL due to a retro-
cochlea (cochlea nerve) damage may occur, although,
this was relatively rare compared to the cochlea damage
[18]. IMRT could deliver higher doses up to 66 Gy to
the IAC if the IAC was not specified as the organ at
risk [19]. This study demonstrated that the IAC mean
doses > 50 Gy showed a trend to increase the incidence
of high frequency (4 kHz) SNHL (RR 2.02 with 95% CI
0.99-4.13). IAC dose limitation was also crucial as the
patients who developed SNHL from cochlea nerve
Table 5 Criteria and radiation doses to the cochlea in correlation with the incidences of SNHL
Study RT Criteria Doses to cochlea Median follow up
& SNHL (per ear)
Kwong et al[10] Conv RT + chemo
(227 ears)
>15 dB at each frequency not defined 30 months
24.2%
Oh et al [19] Conv RT + chemo
(48 ears)
>15 dB at
4 kHz and PTA
mean inner ear dose 66.2 ± 6.2 1 year
29.2%
Ho et al [12] Conv RT + chemo
(526 ears)
>10 dB at
4 kHz and PTA
estimated
70-91 Gy, 2.5-3.5 Gy/F
4.5 years,
4 kHz 60%
PTA 18%
Chan et al [5] Conf RT vs
Conf RT + chemo
(170 ears)
>15 dB at
4 kHz
mean cochlea dose
33-71.7 Gy
24 months
33.3% vs 55%
(Conf RT vs
Conf RT+ chemo)
Chen et al.[4] Conf RT+ chemo
(44 ears)
>20 dB at one frequency
>10 dB at two frequencies
28.4 - 70.0 Gy 29 months
57%
Our study Conv RT +chemo
vs IMRT+ chemo
(134 ears, 68 patients)
>15 db loss at
4 kHz and PTA
Mean cochlea dose 25.09-75.54 Gy (IMRT) 14 months
4 kHz
Conv 48.75%
IMRT 37%
PTA Conv 5%
IMRT 7.4%
Conv RT = Conventional radiation therapy Conf RT = Conformal radiation therapy.
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hearing aid or even a cochlea implantation.
Our study revealed the lower incidence (10.3%) of low
frequency SNHL (PTA). This concurred with the other
series, as the high frequency (> 4 kHz) would be the
earliest sign for damage at the outer hair cells in the
basal turn of the cochlea [19].
Another coexisting factor for high frequency SNHL
was a combination of Cisplatin chemotherapy with RT
from a synergistic effect to the cochlea [4,5,15,20].
Some series reported that 600 mg/m
2 [21] or total
dose of 1,050 mg [22] of Cisplatin increased the inci-
dences of high frequency SNHL. As most of the
patients in this study had locally advanced disease and
received a combination of chemotherapy, the effect of
Cisplatin to SNHL could not be evaluated directly.
There was no apparent increase in the incidence of
SNHL with a total accumulation dose of > 600 mg in
this study. However, a further bivariate analysis
revealed that dose limitation to the cochlea (< 50 Gy)
and inner ear (< 45 Gy) would potentially protect
SNHL in patients who received Cisplatin chemother-
apy to an accumulative dose of > 600 mg.
For the other associated factors, Kwong et al reported
the association of age, sex, and post RT serous otitis
media as significant prognostic factors for persistent
SNHL on multivariate analysis [10]. Nonetheless, this
study could not demonstrate any relationship among
age, evidence of otitis media, and/or medical co-morbid-
ities with the incidence of SNHL.
Lastly, the inter-fraction setup uncertainties for very
small structures are crucial. Radiation dose evaluation
on the computer planning would be only the estimation
of the actual dose delivered to the tiny inner ear during
the radiation course.
Conclusion
Apparently, radiation therapy produces relatively high
incidences of high frequency SNHL. The severities of
the damage are increased with higher radiation doses
delivered to the inner ear structures. Mean radiation
dose constraint of 50 Gy to the cochlea and IAC showed
a trend to decrease the incidences of SNHL, especially
in patients who received combination of Cisplatin che-
motherapy. Normal structures delineation and radiation
dose constraint with modern radiation techniques are
crucial to diminish the long term SNHL and enhance
the quality of life in addition to insuring survival from
the cancer.
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